NeuroBo Pharmaceuticals, Inc., a distinguished biotech firm dedicated to advancing solutions for cardiometabolic diseases, has solidified its leadership team with the permanent appointment of Marshall Woodworth as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer. Woodworth, who previously served as the Acting Chief Financial Officer since October 27, 2023, has seamlessly transitioned into this key role after a successful tenure.
The announcement underscores NeuroBo's commitment to driving forward its innovative research initiatives under the experienced financial leadership of Woodworth. President and CEO Hyung Heon Kim expressed unwavering confidence in Woodworth, highlighting his extensive background in the pharmaceutical and medical device sectors as a crucial asset for achieving NeuroBo's strategic objectives.
Reflecting on his appointment, Woodworth conveyed his enthusiasm for the direction NeuroBo is headed, particularly emphasizing the anticipation surrounding upcoming clinical milestones. His strategic insights and effective financial management during his tenure as Acting CFO have positioned him as an integral part of NeuroBo's continued success.
Bringing a wealth of experience to NeuroBo, Woodworth has held CFO roles at esteemed pharmaceutical companies, including Nevakar, Inc., Braeburn Pharmaceuticals, Inc., Aerocrine AB, and Furiex Pharmaceuticals Inc. His diverse background equips him with a comprehensive understanding of the intricacies of the pharmaceutical and medical device industries.
NeuroBo's current research pipeline showcases its dedication to addressing critical cardiometabolic issues. Key compounds in development include DA-1241, a GPR119 agonist targeting metabolic associated fatty liver disease (MAFLD) and Type 2 Diabetes Mellitus, and DA-1726, an oxyntomodulin analogue designed for obesity treatment. Both compounds have demonstrated promising results in preclinical studies, with DA-1241 impacting liver inflammation and glucose metabolism, while DA-1726 holds potential for superior weight loss due to its dual agonist properties.
Woodworth's appointment as the permanent CFO further solidifies NeuroBo's commitment to advancing transformative therapies in the cardiometabolic space. The company remains at the forefront of pioneering research, with his financial leadership poised to steer NeuroBo towards achieving significant milestones and contributing to the evolving landscape of biotechnology.
